JSM 2005 - Toronto

Abstract #303826

This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.



The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

The Program has labeled the meeting rooms with "letters" preceding the name of the room, designating in which facility the room is located:

Minneapolis Convention Center = “MCC” Hilton Minneapolis Hotel = “H” Hyatt Regency Minneapolis = “HY”

Back to main JSM 2005 Program page
Legend: = Applied Session, = Theme Session, = Presenter
Activity Number: 123
Type: Topic Contributed
Date/Time: Monday, August 8, 2005 : 10:30 AM to 12:20 PM
Sponsor: Section on Health Policy Statistics
Abstract - #303826
Title: On the Utility of Stochastic Models of Chronic Obstructive Pulmonary Disease
Author(s): Rebecca Boehm*+ and Kristin Highland and Kit Simpson and Robert Woolson
Companies: Medical University of South Carolina and Medical University of South Carolina and Medical University of South Carolina and Medical University of South Carolina
Address: Dept. of Biostatistics, Bioinformatics, and Epidemiology, Charleston, SC, 29425, United States
Keywords: Cost-utility analysis ; Markov model ; COPD
Abstract:

Chronic obstructive pulmonary disease (COPD) is a progressive and irreversible lung disorder characterized by reduced lung function, abnormal inflammatory response, dyspnea, increased sputum production, and costly and debilitating exacerbations. Common treatments for COPD include smoking cessation therapy, short- and long-acting bronchodilators, inhaled corticosteroids, pulmonary rehabilitation, and home oxygen therapy. However, a recent metaanalysis demonstrated that inhaled corticosteroids fail to slow the decline in FEV1, the primary clinical marker of COPD progression. In addition, evidence exists to suggest that long-term inhaled corticosteroid use may increase bone density loss, leading to osteoporosis. Given that the side effects of inhaled corticosteroid use may have detrimental effects on patient quality of life and increase direct medical costs while having no effect on the primary clinical marker of disease progression, the wisdom of their widespread use among COPD sufferers has become a topic of hot debate in the pulmonary community. We attempt to address the common clinical questions surrounding the efficacy and side effects of inhaled corticosteroids.

  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2005 program

JSM 2005 For information, contact jsm@amstat.org or phone (888) 231-3473. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2005